BS_850BAHH9
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 11.892247043363994
- age_years
- 0.466
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.624
- IL6_JAK_STAT3_SIGNALING+0.577
- ALLOGRAFT_REJECTION+0.570
- ANGIOGENESIS+0.566
- INTERFERON_GAMMA_RESPONSE+0.541
- INFLAMMATORY_RESPONSE+0.535
- TNFA_SIGNALING_VIA_NFKB+0.517
- IL2_STAT5_SIGNALING+0.478
- INTERFERON_ALPHA_RESPONSE+0.477
- MTORC1_SIGNALING+0.445
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.234
- BILE_ACID_METABOLISM-0.096
- HEDGEHOG_SIGNALING-0.067
- KRAS_SIGNALING_DN-0.049
- OXIDATIVE_PHOSPHORYLATION-0.046
- HEME_METABOLISM-0.044
- SPERMATOGENESIS-0.007
- WNT_BETA_CATENIN_SIGNALING+0.010
- DNA_REPAIR+0.035
- MYOGENESIS+0.044
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.958 |
| 2 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.953 |
| 3 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.951 |
| 4 | SRR934750 | — | — | 0.947 |
| 5 | SRR934903 | — | — | 0.946 |
| 6 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.946 |
| 7 | SRR934845 | — | — | 0.944 |
| 8 | 3D3C3AAA-2C7A-43C6-8137-73A6E0896FAC | — | — | 0.943 |
| 9 | SRR934782 | — | — | 0.942 |
| 10 | SRR934866 | — | — | 0.939 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.624 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.577 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.570 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.566 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.541 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.535 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.517 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.478 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.477 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.445 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.443 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.415 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| APOPTOSIS | 0.403 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.399 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.395 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.388 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.377 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.376 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.373 | Inavolisib | — uncovered |